Pacira Biosciences, Stock Beta

PCRX Stock

USD 17.38 0.35 2.06%

Pacira BioSciences, fundamentals help investors to digest information that contributes to Pacira BioSciences,'s financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira BioSciences,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira BioSciences, stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pacira BioSciences, Company Beta Analysis

Pacira BioSciences,'s Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current Pacira BioSciences, Beta

0.82

Most of Pacira BioSciences,'s fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira BioSciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pacira Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for Pacira BioSciences, is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Beta. Since Pacira BioSciences,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira BioSciences,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira BioSciences,'s interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.96	0.46	0.95	0.32	0.58	0.97	0.96	0.36	0.92	0.86	0.44	0.94	0.63	0.95	-0.03	0.95	0.83	0.88	0.16	0.52	0.88	0.49	0.78
Total Stockholder Equity	0.96		0.5	0.91	0.38	0.6	0.93	0.98	0.39	0.79	0.76	0.26	0.9	0.64	0.97	0.05	0.98	0.81	0.88	0.11	0.33	0.91	0.61	0.88
Current Deferred Revenue	0.46	0.5		0.51	-0.1	0.51	0.47	0.43	0.69	0.36	0.51	-0.16	0.26	0.41	0.36	0.51	0.51	0.67	0.56	0.48	0.11	0.43	0.54	0.35
Net Debt	0.95	0.91	0.51		0.3	0.61	0.96	0.9	0.45	0.88	0.81	0.31	0.88	0.6	0.88	0.02	0.91	0.84	0.85	0.35	0.41	0.9	0.43	0.73
Retained Earnings	0.32	0.38	-0.1	0.3		0.04	0.29	0.37	-0.42	0.18	-0.07	-0.02	0.51	-0.31	0.4	-0.5	0.36	-0.09	0.02	-0.24	-0.12	0.55	0.3	0.6
Accounts Payable	0.58	0.6	0.51	0.61	0.04		0.67	0.6	0.5	0.54	0.6	-0.12	0.5	0.35	0.57	0.29	0.63	0.74	0.73	0.26	0.1	0.54	0.4	0.48
Long Term Debt	0.97	0.93	0.47	0.96	0.29	0.67		0.94	0.34	0.9	0.82	0.31	0.94	0.61	0.93	-0.08	0.93	0.85	0.86	0.17	0.43	0.86	0.45	0.74
Net Receivables	0.96	0.98	0.43	0.9	0.37	0.6	0.94		0.28	0.81	0.74	0.28	0.95	0.63	0.99	-0.09	0.99	0.79	0.86	0.0	0.35	0.89	0.53	0.87
Short Term Investments	0.36	0.39	0.69	0.45	-0.42	0.5	0.34	0.28		0.32	0.58	0.0	0.04	0.54	0.23	0.88	0.34	0.66	0.58	0.73	0.14	0.29	0.41	0.11
Total Liab	0.92	0.79	0.36	0.88	0.18	0.54	0.9	0.81	0.32		0.93	0.63	0.84	0.62	0.78	-0.07	0.77	0.79	0.85	0.27	0.7	0.77	0.28	0.58
Total Current Assets	0.86	0.76	0.51	0.81	-0.07	0.6	0.82	0.74	0.58	0.93		0.6	0.69	0.72	0.71	0.26	0.72	0.87	0.9	0.36	0.7	0.65	0.42	0.49
Short Term Debt	0.44	0.26	-0.16	0.31	-0.02	-0.12	0.31	0.28	0.0	0.63	0.6		0.37	0.28	0.28	-0.12	0.19	0.18	0.32	0.04	0.86	0.21	-0.06	0.06
Intangible Assets	0.94	0.9	0.26	0.88	0.51	0.5	0.94	0.95	0.04	0.84	0.69	0.37		0.48	0.95	-0.34	0.91	0.66	0.75	-0.09	0.39	0.87	0.42	0.82
Common Stock	0.63	0.64	0.41	0.6	-0.31	0.35	0.61	0.63	0.54	0.62	0.72	0.28	0.48		0.61	0.28	0.62	0.8	0.82	0.21	0.32	0.55	0.34	0.49
Property Plant Equipment	0.95	0.97	0.36	0.88	0.4	0.57	0.93	0.99	0.23	0.78	0.71	0.28	0.95	0.61		-0.12	0.98	0.75	0.83	-0.07	0.32	0.88	0.55	0.88
Net Tangible Assets	-0.03	0.05	0.51	0.02	-0.5	0.29	-0.08	-0.09	0.88	-0.07	0.26	-0.12	-0.34	0.28	-0.12		-0.03	0.3	0.25	0.58	-0.03	-0.05	0.34	-0.16
Good Will	0.95	0.98	0.51	0.91	0.36	0.63	0.93	0.99	0.34	0.77	0.72	0.19	0.91	0.62	0.98	-0.03		0.81	0.86	0.06	0.3	0.89	0.54	0.88
Long Term Debt Total	0.83	0.81	0.67	0.84	-0.09	0.74	0.85	0.79	0.66	0.79	0.87	0.18	0.66	0.8	0.75	0.3	0.81		0.94	0.4	0.36	0.71	0.5	0.62
Capital Surpluse	0.88	0.88	0.56	0.85	0.02	0.73	0.86	0.86	0.58	0.85	0.9	0.32	0.75	0.82	0.83	0.25	0.86	0.94		0.27	0.44	0.81	0.49	0.71
Long Term Investments	0.16	0.11	0.48	0.35	-0.24	0.26	0.17	0.0	0.73	0.27	0.36	0.04	-0.09	0.21	-0.07	0.58	0.06	0.4	0.27		0.17	0.19	-0.05	-0.13
Short Long Term Debt	0.52	0.33	0.11	0.41	-0.12	0.1	0.43	0.35	0.14	0.7	0.7	0.86	0.39	0.32	0.32	-0.03	0.3	0.36	0.44	0.17		0.22	-0.15	0.08
Net Invested Capital	0.88	0.91	0.43	0.9	0.55	0.54	0.86	0.89	0.29	0.77	0.65	0.21	0.87	0.55	0.88	-0.05	0.89	0.71	0.81	0.19	0.22		0.54	0.88
Net Working Capital	0.49	0.61	0.54	0.43	0.3	0.4	0.45	0.53	0.41	0.28	0.42	-0.06	0.42	0.34	0.55	0.34	0.54	0.5	0.49	-0.05	-0.15	0.54		0.62
Capital Stock	0.78	0.88	0.35	0.73	0.6	0.48	0.74	0.87	0.11	0.58	0.49	0.06	0.82	0.49	0.88	-0.16	0.88	0.62	0.71	-0.13	0.08	0.88	0.62

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict Pacira BioSciences,

In accordance with the recently published financial statements, Pacira BioSciences, has a Beta of 0.818. This is 4.88% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

Pacira Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences,'s direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics of similar companies.

Pacira BioSciences, is currently under evaluation in beta category among its peers.

Pacira BioSciences, ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pacira BioSciences,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pacira BioSciences,'s managers, analysts, and investors.

Environmental

Governance

Social

Pacira BioSciences, Institutional Holders

Institutional Holdings refers to the ownership stake in Pacira BioSciences, that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pacira BioSciences,'s outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pacira BioSciences,'s value.

		Shares
Rock Springs Capital Management Lp	2024-06-30	785 K
Nuveen Asset Management, Llc	2024-06-30	711.2 K
Hhg Plc	2024-06-30	698.4 K
Schroder Investment Management Group	2024-06-30	616.8 K
Jpmorgan Chase & Co	2024-06-30	600.6 K
Ardsley Advisory Partners	2024-06-30	580 K
Bank Of America Corp	2024-06-30	559 K
Assenagon Asset Management Sa	2024-09-30	553.1 K
Amvescap Plc.	2024-06-30	548.6 K
Blackrock Inc	2024-06-30	8 M
Vanguard Group Inc	2024-09-30	5.3 M

As returns on the market increase, Pacira BioSciences,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Pacira BioSciences, is expected to be smaller as well.

Pacira Fundamentals

	Return On Equity	-0.11
	Return On Asset	0.0417
	Profit Margin	(0.13) %
	Operating Margin	0.13 %
	Current Valuation	963.09 M
	Shares Outstanding	46.17 M
	Shares Owned By Insiders	2.10 %
	Shares Owned By Institutions	97.90 %
	Number Of Shares Shorted	5.46 M
	Price To Earning	14.34 X
	Price To Book	1.03 X
	Price To Sales	1.13 X
	Revenue	674.98 M
	Gross Profit	393.23 M
	EBITDA	162.9 M
	Net Income	41.95 M
	Cash And Equivalents	316.39 M
	Cash Per Share	6.90 X
	Total Debt	586.04 M
	Debt To Equity	1.10 %
	Current Ratio	3.95 X
	Book Value Per Share	16.24 X
	Cash Flow From Operations	154.65 M
	Short Ratio	9.34 X
	Earnings Per Share	(1.98) X
	Price To Earnings To Growth	(3.83) X
	Target Price	18.0
	Number Of Employees	711
	Beta	0.82
	Market Capitalization	786.33 M
	Total Asset	1.57 B
	Retained Earnings	(106.8 M)
	Working Capital	412.61 M
	Current Asset	252.58 M
	Current Liabilities	149.79 M
	Net Asset	1.57 B

About Pacira BioSciences, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC